{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T02:56:49Z","timestamp":1784170609993,"version":"3.55.0"},"reference-count":11,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T00:00:00Z","timestamp":1635897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Acalabrutinib, a second-generation and more selective Bruton's tyrosine kinase inhibitor, was developed to potentiate efficacy while minimizing ibrutinib-associated side effects. We undertook a systematic review and meta-analysis of randomized clinical trials to determine the risks of acalabrutinib-related cardiac toxicities in patients with chronic lymphocytic leukemia. Patients on acalabrutinib experienced higher risk of any-grade cardiac events (risk ratio, 1.75; p = 0.01) while there was a considerable trend toward statistical significance in the risk of any-grade atrial fibrillation (risk ratio, 2.56; p = 0.05). There was no significant increase in the risk of hypertension or high-grade cardiac events or atrial fibrillation in the acalabrutinib group.<\/jats:p>","DOI":"10.36401\/jipo-21-12","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T12:42:27Z","timestamp":1635943347000},"page":"43-47","source":"Crossref","is-referenced-by-count":5,"title":["Acalabrutinib-Related Cardiac Toxicities in Patients with Chronic Lymphocytic Leukemia: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.36401","volume":"5","author":[{"given":"Thura Win","family":"Htut","sequence":"first","affiliation":[{"name":"Department of Haematology, Aberdeen Royal Infirmary, Foresterhill Health Campus, Aberdeen, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myat Min","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Interfaith Medical Center, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Zin","family":"Thein","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"2022051917272954700_i2590-017X-5-2-43-b01","doi-asserted-by":"crossref","unstructured":"Byrd\n              JC,\n            \n            \n              Brown\n              JR,\n            \n            \n              O'Brien\n              S,\n            \n            et al.\n          \n          Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2014;\n\t\t\t\t\t371:\n\t\t\t\t\t213\u2013\n\t\t\t\t\t223.","DOI":"10.1056\/NEJMoa1400376"},{"key":"2022051917272954700_i2590-017X-5-2-43-b02","doi-asserted-by":"crossref","unstructured":"Burger\n              JA,\n            \n            \n              Tedeschi\n              A,\n            \n            \n              Barr\n              PM,\n            \n            et al.\n          \n          Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2015;\n\t\t\t\t\t373:\n\t\t\t\t\t2425\u2013\n\t\t\t\t\t2437.","DOI":"10.1056\/NEJMoa1509388"},{"key":"2022051917272954700_i2590-017X-5-2-43-b03","doi-asserted-by":"crossref","unstructured":"Farooqui\n              M,\n            \n            \n              Valdez\n              J,\n            \n            \n              Soto\n              S,\n            \n            \n              Bray\n              A,\n            \n            \n              Tian\n              X,\n            \n            \n              Wiestner\n              A.\n            \n          \n          Atrial fibrillation in CLL\/SLL patients on ibrutinib.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2015;\n\t\t\t\t\t126:\n\t\t\t\t\t2933.","DOI":"10.1182\/blood.V126.23.2933.2933"},{"key":"2022051917272954700_i2590-017X-5-2-43-b04","doi-asserted-by":"crossref","unstructured":"Archibald\n              WJ,\n            \n            \n              Rabe\n              KG,\n            \n            \n              Kabat\n              BF,\n            \n            et al.\n          \n          Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.\n\t\t\t\t\tAnn Hematol.\n\t\t\t\t\t2021;\n\t\t\t\t\t100:\n\t\t\t\t\t143\u2013\n\t\t\t\t\t155.","DOI":"10.1007\/s00277-020-04094-3"},{"key":"2022051917272954700_i2590-017X-5-2-43-b05","doi-asserted-by":"crossref","unstructured":"Sharman\n              JP,\n            \n            \n              Egyed\n              M,\n            \n            \n              Jurczak\n              W,\n            \n            et al.\n          \n          Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2020;\n\t\t\t\t\t395:\n\t\t\t\t\t1278\u2013\n\t\t\t\t\t1291.","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"2022051917272954700_i2590-017X-5-2-43-b06","doi-asserted-by":"crossref","unstructured":"Ghia\n              P,\n            \n            \n              Pluta\n              A,\n            \n            \n              Wach\n              M,\n            \n            et al.\n          \n          ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2020;\n\t\t\t\t\t38:\n\t\t\t\t\t2849\u2013\n\t\t\t\t\t2861.","DOI":"10.1200\/JCO.19.03355"},{"key":"2022051917272954700_i2590-017X-5-2-43-b07","doi-asserted-by":"crossref","unstructured":"Moher\n              D,\n            \n            \n              Liberati\n              A,\n            \n            \n              Tetzlaff\n              J,\n            \n            \n              Altman\n              DG,\n            \n            The PRISMA Group.\n          \n          Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.\n\t\t\t\t\tPLoS Med.\n\t\t\t\t\t2009;\n\t\t\t\t\t6:\n\t\t\t\t\te1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2022051917272954700_i2590-017X-5-2-43-b08","doi-asserted-by":"crossref","unstructured":"Hendriks\n              RW,\n            \n            \n              Yuvaraj\n              S,\n            \n            \n              Kil\n              LP.\n            \n          \n          Targeting Bruton's tyrosine kinase in B cell malignancies.\n\t\t\t\t\tNat Rev Cancer.\n\t\t\t\t\t2014;\n\t\t\t\t\t14:\n\t\t\t\t\t219\u2013\n\t\t\t\t\t232.","DOI":"10.1038\/nrc3702"},{"key":"2022051917272954700_i2590-017X-5-2-43-b09","doi-asserted-by":"crossref","unstructured":"McMullen\n              JR,\n            \n            \n              Boey\n              EJ,\n            \n            \n              Ooi\n              JY,\n            \n            \n              Seymour\n              JF,\n            \n            \n              Keating\n              MJ,\n            \n            \n              Tam\n              CS.\n            \n          \n          Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.\n\t\t\t\t\tBlood.\n\t\t\t\t\t2014;\n\t\t\t\t\t124:\n\t\t\t\t\t3829\u2013\n\t\t\t\t\t3830.","DOI":"10.1182\/blood-2014-10-604272"},{"key":"2022051917272954700_i2590-017X-5-2-43-b10","doi-asserted-by":"crossref","unstructured":"Farooqui\n              MZ,\n            \n            \n              Valdez\n              J,\n            \n            \n              Martyr\n              S,\n            \n            et al.\n          \n          Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t16:\n\t\t\t\t\t169\u2013\n\t\t\t\t\t176.","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"2022051917272954700_i2590-017X-5-2-43-b11","doi-asserted-by":"crossref","unstructured":"Byrd\n              JC,\n            \n            \n              Hillmen\n              P,\n            \n            \n              Ghia\n              P,\n            \n            et al.\n          \n          First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2021;\n\t\t\t\t\t39(15 suppl):\n\t\t\t\t\t7500.","DOI":"10.1200\/JCO.2021.39.15_suppl.7500"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/5\/2\/43\/3060651\/i2590-017x-5-2-43.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/5\/2\/43\/3060651\/i2590-017x-5-2-43.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:42Z","timestamp":1765475322000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/5\/2\/article-p43.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,4]]},"published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-21-12","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}